A detailed history of Jane Street Group, LLC transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 380,594 shares of RVMD stock, worth $22.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
380,594
Previous 129,467 193.97%
Holding current value
$22.6 Million
Previous $4.17 Million 254.03%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$30.14 - $40.68 $7.57 Million - $10.2 Million
251,127 Added 193.97%
380,594 $14.8 Million
Q1 2024

May 15, 2024

SELL
$26.56 - $33.55 $1.77 Million - $2.24 Million
-66,765 Reduced 34.02%
129,467 $4.17 Million
Q4 2023

Feb 14, 2024

SELL
$18.35 - $34.12 $105,769 - $196,667
-5,764 Reduced 2.85%
196,232 $5.63 Million
Q3 2023

Nov 14, 2023

BUY
$25.17 - $35.05 $2.23 Million - $3.11 Million
88,694 Added 78.28%
201,996 $5.59 Million
Q2 2023

Aug 14, 2023

BUY
$20.28 - $27.0 $1.16 Million - $1.54 Million
57,008 Added 101.27%
113,302 $3.03 Million
Q1 2023

May 15, 2023

BUY
$20.76 - $30.09 $961,208 - $1.39 Million
46,301 Added 463.33%
56,294 $1.22 Million
Q4 2022

Feb 14, 2023

SELL
$17.68 - $25.53 $195,081 - $281,698
-11,034 Reduced 52.48%
9,993 $238,000
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $95,034 - $141,518
5,443 Added 34.93%
21,027 $415,000
Q2 2022

Aug 16, 2022

BUY
$14.54 - $27.17 $48,476 - $90,584
3,334 Added 27.22%
15,584 $304,000
Q1 2022

May 17, 2022

BUY
$17.31 - $26.4 $212,047 - $323,400
12,250 New
12,250 $312,000
Q2 2021

Aug 16, 2021

SELL
$29.0 - $47.44 $206,538 - $337,867
-7,122 Closed
0 $0
Q1 2021

May 18, 2021

BUY
$37.21 - $54.43 $265,009 - $387,650
7,122 New
7,122 $327,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $5.21B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.